Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SGMO 
Sangamo Therapeutics Inc (SGMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SGMO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.1
1 Year Target Price $4.1
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 59.1% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 174.99M USD | Price to earnings Ratio - | 1Y Target Price 4.1 |
Price to earnings Ratio - | 1Y Target Price 4.1 | ||
Volume (30-day avg) 7 | Beta 1.19 | 52 Weeks Range 0.41 - 3.18 | Updated Date 08/15/2025 |
52 Weeks Range 0.41 - 3.18 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.0158 | Actual -0.08 |
Profitability
Profit Margin -77.48% | Operating Margin (TTM) -97.54% |
Management Effectiveness
Return on Assets (TTM) -41.15% | Return on Equity (TTM) -292.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 148040121 | Price to Sales(TTM) 2.14 |
Enterprise Value 148040121 | Price to Sales(TTM) 2.14 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA -1 | Shares Outstanding 301708992 | Shares Floating 294978346 |
Shares Outstanding 301708992 | Shares Floating 294978346 | ||
Percent Insiders 2.16 | Percent Institutions 17.19 |
Upturn AI SWOT
Sangamo Therapeutics Inc
Company Overview
History and Background
Sangamo Therapeutics, Inc. was founded in 1995. It pioneered the development of zinc finger nuclease (ZFN) technology for gene editing. Initially focused on HIV, it evolved to address various genetic diseases and oncology.
Core Business Areas
- Genomic Medicine: Sangamo focuses on developing therapies for genetic diseases through gene editing, gene therapy, cell therapy, and gene regulation.
- ST-920: Development and delivery of treatments, such as ST-920 for Fabry disease using adeno-associated virus (AAV) delivery of a gene therapy for alpha-galactosidase A (GLA).
Leadership and Structure
The leadership team typically includes a CEO, CFO, CSO, and other key executives responsible for various departments. The organizational structure is typically hierarchical, with departments focused on research, development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- ST-920 (Fabry Disease): ST-920 is a gene therapy being developed for Fabry disease, an inherited disorder caused by a deficiency of the alpha-galactosidase A (GLA) enzyme. As a pre-commercial therapy, precise market share data is unavailable. Competitors in the enzyme replacement and gene therapy space include Amicus Therapeutics (FOLD), and Avrobio (AVRO).
Market Dynamics
Industry Overview
The gene editing and gene therapy industry is rapidly growing, driven by technological advancements and increasing investment. Key players include pharmaceutical giants and specialized biotech companies.
Positioning
Sangamo is positioned as a pioneer in gene editing, particularly with its ZFN technology. Its competitive advantage lies in its intellectual property and experience in early gene editing technologies.
Total Addressable Market (TAM)
The gene therapy market is expected to reach billions of dollars in the coming years. Sangamo's positioning with respect to this TAM is focused on capturing market share within specific genetic diseases like Fabry disease and other conditions where its gene editing technology can be applied.
Upturn SWOT Analysis
Strengths
- Pioneering gene editing technology (ZFN)
- Strong intellectual property portfolio
- Experienced management team
- Strategic partnerships with major pharmaceutical companies
Weaknesses
- High cash burn rate
- Reliance on partnerships for funding
- Early-stage pipeline with associated risks
- Regulatory hurdles and evolving landscape for gene editing
Opportunities
- Expansion of pipeline into new therapeutic areas
- Potential for strategic acquisitions or partnerships
- Advancements in gene editing technology and delivery methods
- Increasing regulatory acceptance of gene therapies
Threats
- Competition from other gene editing technologies (e.g., CRISPR)
- Clinical trial failures
- Regulatory delays or rejections
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Sangamo's advantage is its pioneering ZFN technology, but it faces increasing competition from companies using CRISPR and base editing. Its success depends on demonstrating the safety and efficacy of its therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been characterized by technological advancements, strategic partnerships, and expansion into new therapeutic areas.
Future Projections: Future growth is dependent on clinical trial successes, regulatory approvals, and the ability to secure additional partnerships and funding.
Recent Initiatives: Recent initiatives include advancing ST-920 for Fabry disease, exploring new gene editing technologies, and expanding its pipeline through collaborations.
Summary
Sangamo Therapeutics is a pioneer in gene editing, holding strong intellectual property. It is reliant on partnerships for funding, leading to variability. Success is contingent on pipeline advancement and positive clinical outcomes. Sangamo faces intense competition and regulatory scrutiny, demanding careful strategic execution to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry News Articles
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional. Market share estimates are approximate and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sangamo Therapeutics Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2000-04-06 | CEO, President & Director Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.sangamo.com |
Full time employees 183 | Website https://www.sangamo.com | ||
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.